{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.3","upperLimit":"15.7","value":"2.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"Local failure is defined as the combination of primary tumor failure (PTF) or involved lobe failure (ILF). PTF was defined based on meeting two criteria: 1. Local enlargement defined as ≥ 20% increase in the longest diameter of the gross tumor volume (GTV) per computerized tomography (CT), and 2. Evidence of tumor viability. Tumor viability could be affirmed by either demonstrating positron emission tomography (PET) imaging with uptake of a similar intensity as the pretreatment staging PET, or by repeat biopsy confirming carcinoma. PTF included marginal failures occurring within 1 cm of the planning target volume (PTV). ILF is defined as failure beyond the primary tumor but within the involved lobe. Time to local recurrence is defined as time from start of treatment to the the date of local recurrence, last known follow-up (censored), or death without local recurrence (censored).","dispersionType":"95% Confidence Interval","groups":[{"description":"20 Gy per fraction for 3 fractions over 1.5-2 weeks, for a total of 60 Gy","id":"OG000","title":"Stereotactic Body Radiation Therapy (SBRT)"}],"paramType":"NUMBER","populationDescription":"Eligible patients","reportingStatus":"POSTED","timeFrame":"From the start of treatment to 2 years","title":"Rate of Local Recurrence at 2 Years","type":"SECONDARY","unitOfMeasure":"percentage of participants"}